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Staphylococcus aureus is an opportunistic Gram-positive
bacterium which causes a wide variety of diseases ranging
from minor skin infections to potentially fatal conditions such
as pneumonia, meningitis and septicaemia. The pathogen is
a leading cause of nosocomial acquired infections, a problem
that is exacerbated by the existence of methicillin- and glyco-
peptide antibiotic-resistant strains which can be challenging
to treat. Alanine racemase (Alr) is a pyridoxal-50-phosphate-
dependent enzyme which catalyzes reversible racemization
between enantiomers of alanine. As d-alanine is an essential
component of the bacterial cell-wall peptidoglycan, inhibition
of Alr is lethal to prokaryotes. Additionally, while ubiquitous
amongst bacteria, this enzyme is absent in humans and most
eukaryotes, making it an excellent antibiotic drug target. The
crystal structure of S. aureus alanine racemase (AlrSas), the
sequence of which corresponds to that from the highly
antibiotic-resistant Mu50 strain, has been solved to 2.15 A ˚
resolution. Comparison of the AlrSas structure with those of
various alanine racemases demonstrates a conserved overall
fold, with the enzyme sharing most similarity to those from
other Gram-positive bacteria. Structural examination indi-
cates that the active-site binding pocket, dimer interface and
active-site entryway of the enzyme are potential targets for
structure-aided inhibitor design. Kinetic constants were
calculated in this study and are reported here. The potential
for a disulﬁde bond in this structure is noted. This structural
and biochemical information provides a template for future
structure-based drug-development efforts targeting AlrSas.
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1. Introduction
Staphylococcus aureus is a highly pathogenic Gram-positive
coccus which was ﬁrst discovered in the pus of surgical
abscesses by Sir Alexander Ogston in 1883 (Ogston, 1883).
S. aureus frequently colonizes the skin and has a niche
preference for the anterior nares of the nose (Kluytmans et al.,
1997), with persistent nasal carriage occurring in 25–30% of
the population (Gorwitz et al., 2008). S. aureus can cause a
wide variety of diseases ranging from skin infections such as
impetigo and folliculitis to life-threatening diseases such as
severe haemorrhagic pneumonia, meningitis, toxic shock
syndrome and septicaemia (von Rittershain, 1878; Shands et
al., 1980; Lowry, 1998; Lina et al., 1999). Host conditions which
increase the likelihood of a severe S. aureus infection include
factors such as open wounds, immunosupression and surgery
(Laupland et al., 2003; Giacometti et al., 2000). S. aureus is a
common cause of hospital-acquired infection (Lowry, 1998;
Fluitet al., 2001; Brumﬁtt & Hamilton-Miller,1989), a problem
that is exacerbated by the alarming rate at which this
bacterium has developed antibiotic resistance.Of particular concern is the rise in community-acquired
methicillin-resistant S. aureus (MRSA), which has broad
resistance to  -lactam antibiotics, including penicillins and
cephalosporins. In the United States, MRSA is responsible for
nearly 100 000 invasive infections and 19 000 deaths per year
(Klevens et al., 2007). MRSA was ﬁrst reported in the United
Kingdom in 1961 (Jevons, 1961) and has since become a
problem in hospitals worldwide, heavily increasing depen-
dence on vancomycin for treatment (Finland, 1979; Jernigan
et al., 1995; Weinstein & Fridkin, 2001). Further complicating
this problem is the emergence of MRSA strains such as Mu50,
which are also resistant to vancomycin. The ﬁrst case of
MRSA with intermediate resistance to vancomycin (VISA)
was reported in 1996 (Hiramatsu et al., 1997) and the ﬁrst
example of complete resistance to vancomycin (VRSA) was
published in 2003 (Chang et al., 2003). There are limited
alternatives for treating VRSA infections, such as linezolid
and daptomycin; however, these antibiotics can have serious
side effects with prolonged use (Lin et al., 2006; French, 2003;
Echevarria et al., 2005) and resistance to both has been
observed (Skiest, 2006; Hayden et al., 2005; Tsiodras et al.,
2001; Wilson et al., 2003). This emphasizes the importance of
identifying new drug targets for the future development of
antibiotics which could be used to treat antibiotic-resistant
S. aureus infections.
Alanine racemase (EC 5.1.1.1) is a pyridoxal-50-phosphate
(PLP) dependent enzyme which catalyzes the reversible
racemization of l-alanine and d-alanine (Walsh, 1989).
Alanine racemase is ubiquitous amongst bacteria but is absent
in humans and rare in eukaryotes, with exceptions that include
the fungi Tolypocladium niveum and Cochliobolus carbonum
(Hoffmann et al., 1994; Cheng & Walton, 2000), the yeast
Schizosaccharomyces pombe (Uo et al., 2001), bivalve molluscs
(Matsushima & Hayashi, 1992; Nomura et al., 2001) and some
crustaceans (Shibata et al., 2000; Fujita et al., 1997; Yoshikawa
et al., 2002). As d-alanine is an essential component of the
bacterial cell-wall peptidoglycan, inhibition of alanine race-
mase is lethal to those prokaryotic organisms that are
dependent on this enzyme for d-alanine, thus making the
enzyme an attractive antibiotic drug target (Lambert &
Neuhaus, 1972). There are two alanine racemase isozymes in
S. aureus: an anabolic alanine racemase (Alr) that is consti-
tutively expressed at low levels and a catabolic alanine race-
mase (DadX) which is inducible by l-alanine. Gram-negative
bacteria commonly possess both isozymes, in contrast to
Gram-positive bacteria, which usually only possess the
anabolic form of the enzyme (Wasserman et al., 1983).
Structural studies of alanine racemase from bacteria such
as Geobacillus stearothermophilus, Pseudomonas aeruginosa,
Streptococcus lavendulae, Mycobacterium tuberculosis,
Escherichia coli, Bacillus anthracis and Enterococcus faecalis
indicate that the enzyme is a homodimer in its native con-
formation (Shaw et al., 1997; LeMagueres et al., 2003, 2005;
Noda et al., 2004; Wu et al., 2008; Au et al., 2008; Coun ˜ago et
al., 2009; Priyadarshi et al., 2009). Each monomer has two
domains: an  / -barrel at the N-terminus and a C-terminal
domain which is predominantly  -stranded. The enzyme has
two active sites, which are formed by interactions between
the N-terminal domain of one monomer and the C-terminal
domain of its partner. In both active sites the essential PLP
cofactor resides in the mouth of the  / -barrel, forming an
N0-pyridoxyl-lysine-50-monophosphate (LLP)residueresulting
from an internal aldimine linkage between PLP and a highly
conserved catalytic lysine.
Numerous kinetic studies of G. stearothermophilus alanine
racemase support the utilization of a stepwise two-base
mechanism by the enzyme, in which a highly conserved active-
site lysine and tyrosine act as general acid/base catalysts. These
residues assume the role of either donating or abstracting an
 -hydrogen from the substrate, depending on the direction in
which the reaction is proceeding (Watanabe et al., 1999, 2002;
Sun & Toney, 1999; Spies & Toney, 2003).
Compounds shown to inhibit alanine racemase include the
natural antibiotics d-cycloserine (DCS) and O-carbamoyl-d-
serine (Neuhaus, 1967) and alanine analogues such as alanine
phosphonate (Copie ´ et al., 1988),  -ﬂuoroalanine,  -chloro-
alanine (Wang & Walsh, 1978) and  , , -triﬂuoroalanine
(Faraci & Walsh, 1989). Structural studies of alanine racemase
with DCS bound indicate that its inhibition results from the
formation of a stable covalent adduct between the antibiotic
and PLP (Fenn et al., 2003).
DCS is marketed for the treatment of M. tuberculosis
infection; however, it has limited use as it can cause severe
central nervous system toxicity (Newton, 1975; Yew et al.,
1993), which appears to arise from the inhibition of human
enzymes that utilize PLP as a cofactor (Lambert & Neuhaus,
1972; Wang & Walsh, 1978). Other inhibitors which are not
used clinically such as alanine phosphonate and propionate
also target PLP and thereby suffer from the same lack of
speciﬁcity (Stamper et al., 1998; Morollo et al., 1999). This
emphasizes the need for the development of new inhibitors for
alanine racemase with greater speciﬁcity, which may translate
into less toxicity to humans.
Here, we report the successful puriﬁcation, crystallization,
structure determination and kinetic characterization of
S. aureus alanine racemase from the Mu50 strain (AlrSas),
which exhibits resistance to both methicillin and glycopeptide
antibiotics. Elucidation of the crystal structure of this enzyme
is an important prerequisite for future structure-based drug-
design efforts targeting S. aureus Alr.
2. Methods
2.1. Protein overexpression and purification
E. coli BL21 (DE3) cells were transformed with pMB1978
(obtained from Professor Michael Benedik, Texas A&M
University), which contained the AlrSas gene inserted into
a pET26b background. Cells grown overnight at 310 K were
used to inoculate the main culture, which was induced with
IPTG at an OD600 of 0.5. Following expression for 14 h, the
cell pellet was collected by centrifugation and the cells were
lysed via sonication. After ammonium sulfate cuts of 30 and
70%, the resuspended pellet containing AlrSas was dialysed
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exchange, hydrophobic interaction and ﬁnally size-exclusion
chromatography. Peak fractions with greater than 95% purity
as shown by SDS–PAGE were pooled and dialysed against
20 mM Tris–HCl pH 7.6 before crystallization.
2.2. Crystallization
Puriﬁed AlrSas was concentrated to 12 mg ml
 1 using a
Vivaspin 2 concentrator (10 000 Da molecular-weight cutoff;
GE Healthcare) and sitting drops were set up versus 100 mM
sodium acetatetrihydratepH 5.0and1.8 M ammoniumsulfate.
Deep yellow crystals of 0.5   0.2   0.1 mm in size grew within
7 d and were cryoprotected by soaking them in mother liquor
containing stepwise increasing amounts of glycerol from 5
to 30%.
2.3. Data collection and processing
A native AlrSas data set was collected at 110 K on a Rigaku
MicroMax-007 HF X-ray generator equipped with a rotating
copper anode and Rigaku R-AXIS IV
++ detector (Rigaku,
Japan), using an oscillation angle of 0.5  and an exposure time
of 5 min per image. Diffraction images were processed with
iMOSLFLM (Battye et al., 2011), POINTLESS (Grosse-
Kunstleve et al., 2002) and SCALA (Evans, 2006) within the
CCP4 suite (Winn et al., 2011). The crystals of AlrSas belonged
to the orthorhombic space group P212121 and diffracted to
2.15 A ˚ resolution. Their unit-cell parameters were a = 65.1,
b = 113.9, c = 126.0 A ˚ ,   =   =   =9 0  . Data-collection and
processing statistics are presented in Table 1.
2.4. Structure determination and refinement
The structure of AlrSas was solved via molecular replace-
ment with Phaser (McCoy et al., 2007) using the monomer of
G. stearothermophilus Alr (with the PLP cofactor and waters
removed), to which it has a sequence identity of 44%, as the
search model. This was performed assuming two monomers
per asymmetric unit, as suggested by the resulting Matthews
coefﬁcient VM of 2.78 A ˚ 3 Da
 1 (Matthews, 1968). PHENIX
v.1.6.1 (Adams et al., 2010) was used to build the initial model.
After several rounds of manual model building using Coot
(Emsley & Cowtan, 2004) and reﬁnement using REFMAC5
(Murshudov et al., 2011), the electron density improved and
waters, the cofactor N0-pyridoxyl-lysine-50-monophosphate,
acetate and sulfate molecules were incorporated into the
structure. The ﬁnal structure had an R factor of 18.9% and
an Rfree value of 23.7%. Intermonomer interactions were
analysed using the Protein Interfaces, Surfaces and Assemblies
service (PISA) at the European Bioinformatics Institute
(http://www.ebi.ac.uk/pdbe/prot_int/pistart.html; Krissinel &
Henrick, 2007). The ﬁnal model was validated using
PROCHECK (Laskowski et al., 1993), with the resulting
Ramachandran plot indicating that 90.4% of the residues are
in the most favoured regions, with the remaining 9.6%
in additionally allowed regions. Additional structure-
determination and reﬁnement statistics are presented in
Table 1.
2.5. Enzyme kinetics
The kinetic parameters Km and Vmax were determined using
a spectrophotometric assay based on Esaki & Walsh (1986)
and as described in our previous work (Strych et al., 2000,
2001). Substrate concentrations of l- and d-alanine (10, 5, 2.5,
1.6 and 1.0 mM) were assayed in triplicate using 20 ng AlrSas
per reaction. The consumption or production of NADH
(340 nm) was monitored for 10 min at 303 K, after which the
kinetic constants Km and Vmax were determined using linear
regression to a Lineweaver–Burk model as well as using non-
linear regression ﬁtting carried out within GraphPad Prism v.5
(GraphPad Software, La Jolla, California, USA).
2.6. Dynamic light scattering
Dynamic light scattering (DLS) was performed using a
DynaPro-99 system (Wyatt Technologies). Puriﬁed AlrSas
(1 mg ml
 1) was ﬁltered with a 0.02 mm Anotop ﬁlter
(Whatman) and added to a quartz light-scattering cuvette at
293 K. DYNAMICS software was used to calculate the radius
of hydration, molecular weight and percent polydispersity.
2.7. Mass spectrometry
To prepare the sample for MALDI–TOF analysis, crystals
of AlrSas were washed, crushed, dissolved in 20 mM Tris–HCl
pH 7.5 and run on an SDS–PAGE gel. The AlrSas band was
excised and digested with trypsin, after which a solution
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Table 1
Data-collection and reﬁnement statistics.
Values in parentheses are for the highest resolution shell.
Space group P212121
Unit-cell parameters
a (A ˚ ) 65.1
b (A ˚ ) 113.9
c (A ˚ ) 126.0
  =   =   ( )9 0
Observations 187093 (24483)
Unique reﬂections 49388 (6693)
Completeness (%) 96.1 (91.0)
Rmerge† (%) 5.8 (19.4)
hI/ (I)i 15.2 (6.3)
Multiplicity 3.8 (3.7)
Resolution range (A ˚ ) 51.91–2.15 (2.27–2.15)
R factor‡ (%) 18.9
Rfree (%) 23.7
Average B factors (A ˚ 2)
Wilson B factor 26.7
Main chain 20.3
Side chains 22.5
Waters 22.6
R.m.s. deviations
Bond lengths (A ˚ ) 0.014
Bond angles ( ) 1.35
No. of residues
Protein atoms 5644
PLP atoms 30
Acetate atoms 8
Sulfate atoms 65
Water atoms 266
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ.‡ R =
P
hkl
   jFobsj j Fcalcj
   = P
hkl jFobsj.consisting of 30% acetonitrile and 0.1% triﬂuoroacetic acid
was added to the samples. The digested solution was mixed
with a matrix solution comprised of 10 mg ml
 1  -cyano-
4-hydroxycinnamic acid dissolved in 65% acetonitrile
(containing 0.1% triﬂuoroacetic acid and 10 mM ammonium
dihydrogen phosphate). This mixture was applied onto a
MALDI sample plate and air-dried. MS analysis of the
samples was performed using a 4800 MALDI tandem time-
of-ﬂight analyzer (MALDI–TOF/TOF). For disulﬁde-bond
analysis a 1 mg ml
 1 sample of AlrSas in solution was prepared
as above, with the addition of an additional step prior to
tryptic digestion in which the sample was alkylated with
20 mM iodacetamide. The resulting sample was analyzed using
an LTQ-Orbitrap (MS/MS) instrument coupled to a nanoﬂow
liquid-chromatography system.
3. Results and discussion
3.1. Overall structure of S. aureus alanine racemase
The tertiary structure of S. aureus alanine racemase (AlrSas)
is a homodimer comprised of two identical monomers (Fig. 1),
consistent with previous crystallographic studies of alanine
racemases (Shaw et al., 1997; LeMagueres et al., 2003, 2005; Wu
et al., 2008; Coun ˜ago et al., 2009). However, despite numerous
structural studies having indicated that the enzyme is dimeric,
there have been reports of some alanine racemases having
a different tertiary structure in solution. In particular, the
alanine racemases from T. niveum and Corbicula japonica
have been suggested to be either
trimeric or tetrameric in solution
(Hoffmann et al., 1994). In order
to determine the oligomeric
state of AlrSas in solution, we
performed dynamic light scat-
tering (DLS), which yielded a
monodisperse single peak
accounting for 98.6% of the
sample mass, with a radius of
hydration of 3.7 nm and a calcu-
lated molecular mass of 73 kDa.
As the hypothetical molecular
weight of the AlrSas monomer is
42.8 kDa, this result is most
consistent with the enzyme being
predominantly dimeric in solu-
tion.
Inspection of our X-ray struc-
ture revealed that the AlrSas
homodimer has two active sites,
both of which are comprised of
residues from the N-terminal
domain of one monomer and
residues from the C-terminal
domain of the second monomer.
In this way, both monomers
contribute to the entryway and
active site of the enzyme (Fig. 1b). Each AlrSas monomer is
comprised of two distinct domains. The N-terminal domain
corresponds to residues 1–241 in the structure and consists
of an eight-stranded  / -barrel. The essential PLP cofactor
is covalently bound to the highly conserved catalytic lysine
(Lys39) via an internal aldimine linkage and extends towards
the centre of the  / -barrel. The C-terminal domain consists
of residues 242–382 and has a secondary structure that is
predominantly  -stranded. This region contains three anti-
parallel  -sheets, with the exception of one  -sheet in which
two out of the ﬁve  -strands are parallel (Fig. 1a). The indi-
vidual AlrSas monomers are crystallographically distinct and
form a dimer in the asymmetric unit. Following reﬁnement
they have a low r.m.s difference of 0.41 after C
 -atom super-
position.
The AlrSas structure is lacking clear density for residues
170–176 and 257–274 in both monomers and these regions are
indicated by red boxes in Fig. 2. Important amino acids in
these missing areas include Ala171, Asp173 and the highly
conserved catalytic tyrosine Tyr2650. These residues are
known from previous structural studies to contribute to the
active-site entryway. The missing density in the N-terminus
(170–176) in other known alanine racemase structures corre-
sponds to a small loop in the  / -barrel between  -strand 7
and helix 8, whereas the C-terminal region (257–274) usually
contains additional  -structure between  -strands 11 and 12
(Shaw et al., 1997; LeMagueres et al., 2003, 2005; Coun ˜ago et
al., 2009). As the overall monomer topology is very similar
between AlrSas and the other enzymes, it is likely that AlrSas
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Figure 1
(a) Structure of the S. aureus alanine racemase monomer. Ribbon representation with  -helices coloured
orange and  -sheets shown in green. The PLP cofactor covalently bound to Lys39 is shown as a black stick
model. (b) Ribbon representation of the S. aureus alanine racemase dimer. Monomers are coloured blue
and green, with the surface representation of one monomer also shown in green. The PLP cofactors are
depicted as black stick models. Sulfate and acetate molecules are shown as ball-and-stick models; C atoms
are coloured black, O atoms red, S atoms yellow and phosphates orange.would also have the same secondary structure in these areas.
Similar regions were missing in the structure reported for
AlrMtb, but the missing regions were not observed in both
monomers. Notably, mass-spectrometric analysis of samples
from crushed AlrSas crystals conﬁrmed the presence of both
regions that are missing density in the crystal structure.
Two acetate molecules and 13 sulfates were modelled into
the AlrSas structure. This observation was not surprising as
sodium acetate trihydrate and ammonium sulfatewerepresent
in the crystallization conditions. Analysis of the positions of
these sulfates showed that all but one is found in the same
position in both monomers and they maintain the same non-
covalent interactions. Eight sulfates are located in solvent-
exposed areas, whereas the remaining four are found within
the dimer interface of AlrSas. One sulfate is located on a point
of symmetry in the dimer interface and interacts with Arg362
and Ser361 from both monomers. Sulfate molecules are also a
feature of the alanine racemase structure from E. coli (Wu et
al., 2008), but there are only three sulfates per monomer, none
of which are in the same location in these two structures.
During the early stages of the reﬁnement, we noted weak
positive density between Cys201 and Cys215 in each
monomer. As the reﬁnement progressed the intra-sulfur
density diminished and the residues were built as cysteine not
cystine. The ﬁnal reﬁned electron density and geometry are
most consistent with cysteine, but we do note an intra-sulfur
distance of 3.2 A ˚ , which is less than the sum of the van der
Waals radii of the two sulfurs. To help address the disulﬁde
question, we investigated alkylated and unalkylated digests of
AlrSas using mass spectrometry (data not shown). The results
of this study were more supportive of cysteines at these
positions, but could not rule out some degree of disulﬁde
formation.
Disulﬁde-bond formation has not been observed at this, or
any other, position in any alanine racemase studied to date.
There is no suggestion that this bond would have any role in
catalysis or regulation. Furthermore, these two cysteines are
not conserved in other alanine racemases, which effectively
rules out an important role for a disulﬁde at this position. We
note that there is an unpublished S. aureus Alr structure
solved to 2.37 A ˚ resolution in the
Protein Data Bank (PDB) which
was also crystallized at pH 5.0
(PDB entry 3oo2; Center for
Structural Genomics of Infectious
Diseases, unpublished work). In
this structure a disulﬁde bond is
reported between these two resi-
dues, but an account of this
structure has not yet been
published and no further infor-
mation is available. In our view,
the most consistent interpretation
of the data described above is
that the structure may contain a
mixture of disulﬁde and dithiol
forms depending on the local
environment but that these two
cysteines are found predomi-
nantly in their reduced form in
the AlrSas structure that we report
here.
3.2. Structural and biochemical
comparison with closely related
alanine racemases
3.2.1. Structural comparisons.
Superposition of the C
  atoms
from the AlrSas monomerwith the
anabolic alanine racemases from
G. stearothermophilus (AlrGst),
B. anthracis (AlrBax) and M.
tuberculosis (AlrMtb), and the
catabolic alanine racemase from
P. aeruginosa (DadXPao) indi-
cates a high level of structural
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Figure 2
Structure-based sequence alignment of alanine racemases from S. aureus (Alr_Sas), G. stearothermophilus
(Alr_Gst), B. anthracis (Alr_Bax), M. tuberculosis (Alr_Mtb) and P. aeuruginosa (DadX_Pao). Identical
residues are shaded black, while grey shading indicates amino acids with conserved physicochemical
properties. The purple box encloses the conserved PLP-binding motif and the red boxes correspond to
missing density in the AlrSas structure. I and M represent residues that form the inner and middle layers of
the active-site entryway. The asterisk marks the highly conserved PLP-bound lysine,the diamond marks the
location of the catalytic tyrosine and the bullet point indicates the location of a residue which is often
carbamylated in alanine racemases which have a lysine at this position. The secondary structure
corresponding to the amino-acid sequence of AlrSas is shown, with  -helices coloured orange and  -strands
coloured green. Residues involved in the dimer interface are shown as blue letters.identity between the enzymes. As shown in Table 2, the AlrSas
monomer is most similar structurally to those of AlrGst and
AlrBax, with which it has highest percent amino-acid sequence
identity. The AlrSas monomer shares somewhat less structural
identity when compared with AlrMtb and DadXPao, as indi-
cated by the higher r.m.s. differences and lower percent
sequence identities. The structure-based sequence alignment
presented in Fig. 2 indicates important residues that are
conserved across these enzymes. Such conserved regions
include the PLP-binding motif consisting of residues AVV-
KANAYGHG, which is located at the beginning of the  / -
barrel domain. This motif contains the highly conserved
catalytic lysine (Lys39) covalently bound to the essential PLP
cofactor. The nonconserved differences in this sequence are
Asn41, which is an aspartate in AlrMtb and DadXPao, Ala40
and Gly46, which are a glycine and an aspartate, respectively,
in AlrBax, and Leu45, which is a histidine in the other listed
structures.
Comparison of the alanine racemase monomers indicates
that they share very similar overall topology. C
 -atom super-
positions of the individual domains and active-site residues
from AlrSas with those of the other structures are presented in
Table 2. As was the case with whole monomers, the individual
domains of AlrSas are the most similar structurally to those
from the Gram-positive bacteria
AlrGst and AlrBax, as indicated by
the low r.m.s. differences for the
N-terminal and C-terminal
regions. The individual domains
of AlrSas share less structural
similarity with AlrMtb and
DadXPao, having higher r.m.s.
differences for both domains. In
each comparison the C-terminal
domains were shown to consis-
tently superpose better than the
N-terminal domains, with both
regions having lower r.m.s.
differences compared with whole
monomers. However, the active-
site residues of all of the alanine
racemases surveyed superpose
particularly well with AlrSas, with
low r.m.s. differences. When
compared with the higher r.m.s.
differences observed for super-
positions involving the whole
monomers and individual
domains of these alanine race-
mases, this demonstrates the
ability of these enzymes to
tolerate deviations between
domains while still retaining very
similar active sites (LeMagueres
et al., 2003).
3.2.2. Structural deviations.
The individual N-terminal and
C-terminal domains of AlrSas
and the other alanine racemases
generally superpose well, but
there are three notable examples
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Figure 3
C
 -atom superpositions of AlrSas and other alanine racemases. S. aureus, green; G. stearothermophilus,
blue; B. anthracis, red; M. tuberculosis, orange; P. aeruginosa, purple. C
 -atom traces showing
superpositions between the (a) N-terminal and (b) C-terminal domains. Regions corresponding to
signiﬁcant structural deviations and their location in the AlrSas structure are labelled. (c) Superposition of
the N-terminal  / -barrel domain of whole alanine racemase monomers visualized as a ribbon
representation. The PLP cofactor of AlrSas is depicted as a black stick model.
Table 2
Average r.m.s. differences (A ˚ ) between the C
  atoms of AlrSas and other
alanine racemases.
The numbers in parentheses denote sequence identity with AlrSas. Residues
from the other structures equivalent to those in AlrSas were used for the
superpositions.
Alanine
racemase
PDB
code
Whole
monomers†
N-terminal
domain‡
C-terminal
domain§
Active
site}
AlrGst 1sft 1.34 (44%) 1.25 (44%) 0.71 (48%) 0.48 (70%)
AlrBax 3ha1 1.54 (43%) 1.47 (43%) 0.75 (46%) 0.53 (68%)
AlrMtb 1xfc 1.67 (33%) 1.62 (32%) 1.13 (36%) 0.72 (51%)
DadXPao 1rcq 2.14 (30%) 1.60 (29%) 1.36 (32%) 0.82 (47%)
† Calculated using monomer A. ‡ Calculated using residues 2–241. § Calculated
using residues 242–382. } Calculated using residues 37–43, 61–65, 82–86, 101–105, 127–
140, 163–171, 198–205, 216–223 and 351–358 from monomer A and residues 263–266,
309–314 and 283–287 from monomer B.of structural divergence between these enzymes (Fig. 3a). The
ﬁrst example is near the N-terminus (residues 2–7), within
which the AlrSas structure deviates signiﬁcantly from that of
DadXPao but superposes well with those of other alanine
racemases. The reason for this difference could be attributed
to the fact that DadXPao has fewer residues in this area
compared with the other enzymes. As illustrated in Fig. 2, this
region contributes to the dimer interface in each of the
structures. The second and third examples relate to two loop
regions (residues 120–123 and 213–215) of the AlrSas structure
which deviate from each of the compared alanine racemases.
PDBePISA analysis (Krissinel & Henrick, 2007) veriﬁes that
both of these loop regions are in solvent-exposed areas which
do not contribute to the dimer interface of the protein (Fig. 2).
The B factors for region 120–123 are 39 A ˚ 2 (main chain) and
45 A ˚ 2 (side chains), which are high compared with those of the
overall structure of AlrSas (main-chain atoms, 20.3 A ˚ 2; side-
chain atoms, 22.5 A ˚ 2), suggesting that this area is ﬂexible. In
contrast, the B factors for region 213–215 do not differ
signiﬁcantly from those of the overall structure (25 and 29 A ˚ 2
for the main chain and side chains, respectively).
In the C-terminal domain there are two main examples of
structural divergence (Fig. 3b). The ﬁrst example is a small
loop in AlrSas (residues 319–323) which superimposes rela-
tively well with the other alanine racemases with the exception
of AlrMtb.I nA l r Mtb this solvent-exposed loop is three amino
acids longer than the equivalent region in AlrSas. The struc-
tural divergence in this region of AlrMtb is likely to be the
result of a more complicated secondary structure in this area,
which is a combination of  -structure and loop (LeMagueres
et al., 2005) rather than purely loop as is observed for AlrSas.
The second example of structural divergence in the C-terminal
domain is a solvent-exposed loop corresponding to residues
334–339 in the AlrSas structure which divergesfrom each of the
other alanine racemases. The B factors in this area of AlrSas
are 21.0 A ˚ 2 (main chain) and 22.9 A ˚ 2 (side chains), which are
not high compared with those of the whole structure. There
are no crystal contacts in this region and the density is of good
quality. Overall, the areas of AlrSas which show the greatest
structural differences from the other alanine racemases are
solvent-exposed loop regions predominantly located towards
the ends of the individual domains, which are not involved
in dimerization (with the exception of loop 2–7) and do not
contribute to the active-site region of the enzyme. As these
areas are generally less important in terms of enzymatic
function, they may be more tolerant of such structural
deviations.
3.2.3. Hinge angle. Each enzyme monomer has a char-
acteristic hinge angle between its N- and C-terminal domains,
as presented in Fig. 3(c), which is the reason that individual
monomers of the enzyme are unable to be optimally super-
imposed. AlrSas has a hinge angle of 128.9 , which is inter-
mediate between those of AlrGst and AlrBax, which have hinge
angles of 129.4 and 127.6 , respectively. The interdomain angle
has less similarity to that of AlrMtb (130.9 ) and differs most
markedly from that of DadXPao (133.9 ), with which
it consistently had the highest r.m.s. differences in terms of
tertiary structure. The differences between these hinge angles
are small in absolute terms, but the availability of two AlrBax
structures solved independently in different space groups
showing the same hinge angle suggests that this feature of
these enzymes is genuine (Au et al., 2008; Coun ˜ago et al.,
2009). These distinct hinge angles are proposed to be medi-
ated in part by hydrogen bonding between the N- and
C-terminal tails of opposite monomers (Le Magueres et al.,
2003). Longer alanine racemases such as AlrSas,A l r Gst and
AlrBax that have extra residues in these regions are able to
form these bonds, resulting in very similar hinge angles.
Shorter alanine racemases such as AlrMtb and DadXPao lack
the equivalent residues, particularly those found in the
C-terminus, and cannot form these bonds.
3.2.4. Enzyme kinetics. Kinetic characterization of AlrSas
revealed a Vmax of 250 U mg
 1 and a Km of 2.77 mM for
the racemization of l-alanine to d-alanine and a Vmax of
91 U mg
 1 and a Km of 0.89 mM for the opposite direction. It
is noted that the activity of AlrSas differs most markedly
from that of AlrGst (l!d Vmax = 2550 U mg
 1; d!l
Vmax = 1400 U mg
 1), with which it shares the most similarity
structurally (Table 3). Also, the l-alanine to d-alanine direc-
tion is kinetically favoured in AlrSas, which makes evolu-
tionary sense as this enzyme is the sole metabolic source of d-
alanine, an essential cell-wall component. This is in agreement
with the trend observed for AlrGst and contrasts with AlrMtb
(l!d Vmax =0 . 5 1U m g
 1; d!l Vmax =0 . 4 6 U m g
 1)
and DadXPao (l!d Vmax = 155 U mg
 1; d!l
Vmax = 134 U mg
 1), in which neither direction of the race-
mization is favoured. Such inferences are unable to be drawn
regarding AlrBax as only the l-alanine to d-alanine direction of
the racemization has been characterized (Vmax = 101 U mg
 1).
The range of values of Keq calculated using the Haldane
relationship for these enzymes is very close to one (between
0.89 and 1.16), as would be expected for a racemization
reaction. Remarkably, despite high levels of sequence identity
and very similar active-site structures, there can be up to three
orders of magnitude difference in terms of their catalytic rates
(Inagaki et al., 1986; Strych et al., 2000, 2001; Coun ˜ago et al.,
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Table 3
Kinetic parameters for the racemization between l-alanine and d-alanine
by alanine racemases.
NR: value not reported.
l!d direction d!l direction
Alanine racemase
Km
(mM)
Vmax
(U mg
 1†)
Km
(mM)
Vmax
(U mg
 1†) Keq‡
AlrSas§ 2.77 250 0.89 91 0.89
AlrGst} 4.25 2550 2.67 1400 1.14
AlrBax†† 2.8 101 NR NR NR
AlrMtb‡‡ 1.2 0.51 1.1 0.46 1.02
DadXPao§§ 1.40 155 1.40 134 1.16
† One unit is deﬁned as the amount of enzyme which catalyzes the racemization of
1 mmol of substrate per minute. ‡ Keq = Vmax(l!d)   Km(d!l)/Vmax(d!l)  
Km(l!d). § Current work; assay performed at 303 K. } Inagaki et al. (1986); assay
performed at 310 K. †† Coun ˜ago et al. (2009); assay performed at 296 K. ‡‡ Strych et
al. (2001); assay performed at 296 K. §§ Strych et al. (2000); assay performed at
296 K.2009). Comparison of the hinge angle and kinetic constants of
AlrSas with those of the other alanine racemases shows that
there is no relationship between these factors, but a recent
publication involving seven different alanine racemases
demonstrated a positive correlation between dimerization
afﬁnity and increased catalytic rate (Ju et al., 2011).
3.2.5. Dimer interface. Mutational studies of alanine race-
mases from E. coli and P. aeruginosa have demonstrated
that dimerization is essential for enzyme activity (Strych &
Benedik, 2002). The structure-based sequence alignment
represented in Fig. 2 indicates that numerous residues which
are involved in dimerization are highly conserved across the
compared alanine racemases.
The area of the dimer interface of AlrSas is 2510 A ˚ 2, which
is smaller than those in AlrGst (3083 A ˚ 2) and AlrBax (3529 A ˚ 2)
but larger compared with AlrMtb and DadXPao (1927 and
1917 A ˚ 2, respectively). The larger area of dimerization for
AlrGst and AlrBax has previously been attributed to these
enzymes having extra residues in the N- and C-termini
involved in the interface which are not present in shorter
enzymes such as DadXPao (LeMagueres et al., 2003; Coun ˜ago
et al., 2009). Fig. 2 indicates that these additional N- and
C-terminal residues are also present in the AlrSas structure.
Calculation of the dimer interface of AlrSas is problematic as
it contains missing density in some regions of each monomer
that are conserved and that contribute to the dimer interface
in the other alanine racemases. To address this issue, we
performed PDBePISA analysis (Krissinel & Henrick, 2007)
taking the absent density from AlrSas into account. This was
achieved by modifying the PDB ﬁles of the other alanine
racemases to remove the regions equivalent to those shown
to be missing in the AlrSas structure. When this change was
included in the calculation of the dimer interfaces the result
for AlrSas (2510 A ˚ 2) was most comparable to that of AlrGst
(2579 A ˚ 2), with which it also shares the most structural simi-
larity. The interface is still smaller compared with that in
AlrBax (2920 A ˚ 2) and larger than those in AlrMtb and DadXPao
(1625 and 1614 A ˚ 2, respectively), albeit to a lesser degree in
each case. Disruption of dimerization has been successfully
employed as a strategy to inhibit protein drug targets in
diseases such as HIV (Song et al., 2001; Boggetto & Reboud-
Ravaux, 2002). The absolute requirement of dimerization for
alanine racemase function and the high level of conservation
across these enzymes makes the dimer interface a possible
target for structure-aided drug design.
3.3. Active site
The active-site residues of AlrSas and the other alanine
racemases superpose particularly well with low r.m.s. differ-
ences, as indicated in Table 2 and Fig. 4(a). The active-site
structure of AlrSas is most similar to those of AlrGst (r.m.s.d.
0.48 A ˚ ) and AlrBax (r.m.s.d. 0.53 A ˚ ), with which it has the
highest percent amino-acid sequence identity (70 and 68%,
respectively). AlrSas shares less similarity with AlrMtb (r.m.s.d.
0.72 A ˚ , 51% sequence identity) and diverges most from
DadXPao (r.m.s.d. 0.82 A ˚ , 47% sequence identity), in accor-
dance with the other C
 -atom superpositions. As mentioned
above, the enzyme active site is comprised of residues from
both monomers, several of which are involved in the
hydrogen-bond network of the PLP cofactor.
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Figure 4
Active site of S. aureus alanine racemase. (a) Superposition of the active-site residues of alanine racemases from S. aureus (green), G. stearothermophilus
(blue), B. anthracis (red), M. tuberculosis (orange) and P. aeruginosa (purple). The chloride present in the AlrBax structure is shown as a pale green
sphere. Residues labelled in red boxes lack density in the AlrSas structure. (b)2 Fo   Fc electron-density map of the active site contoured at 1.0 . The side
chains of the AlrSas active site are depicted as sticks; C atoms are coloured green, O atoms red, N atoms blue, S atoms yellow and phosphate orange. The
PLP cofactors from each structure are depicted as ball-and-stick models. Important water molecules that are alluded to in the text are shown as grey
spheres. In both panels the acetate and sulfate from the AlrSas structure are represented as ball-and-stick models; C atoms are coloured black, O atoms
red and S atoms yellow. Primed numbers denote residues that are contributed by the second monomer.Fig. 4(b) depicts the active-site structure of AlrSas, in which
PLP is bound to the enzyme via an internal aldimine formed
between the C40 atom of the cofactor and Lys39 NZ. The
internal aldimine is also within hydrogen-bonding distance of
the phenolic O atom of PLP, which interacts with an ordered
water molecule found in both active sites (wat2031 and
wat2135). The cofactor exists in a dynamic equilibrium
between the externally and internally reacted aldimine forms
(LeMagueres et al., 2003) and is capable of catalyzing reac-
tions other than racemization, such as transamination and
decarboxylation. As PLP alone is sufﬁcient to catalyze these
reactions, it has been suggested that the holoenzyme plays a
critical role in controlling the reaction speciﬁcity of the co-
factor (Toney, 2005). In alanine racemases the catalytic lysine
and tyrosine are situated on opposite sides of the pyridine
ring, which is proposed to aid in racemization being favoured
over other PLP-dependent reactions (Shaw et al., 1997). In the
AlrSas structure the phosphate tail of PLP is stabilized by
interactions with residues from the ﬁrst monomer. Of the
three phosphate-group O atoms, OP1 hydrogen bonds to
Ile222 NH and Tyr43 OH, OP2 interacts with Tyr354 OH and
OP3 hydrogen bonds to Ser204 OH and NH. In addition, OP3
hydrogen bonds to a water molecule (wat2032) which also
interacts with Ser204 NH and the side chain of Asn203.
The pyridine ring N1 of the PLP in AlrSas is further stabi-
lized via a hydrogen bond to the side chain of Arg219. This
residue is in turn held in place by interactions with His200 and
His168, the latter of which has been shown to interact with the
phenolic O atom of Tyr2650 in other structures (Shaw et al.,
1997; LeMagueres et al., 2003). Mutational studies of this
arginine in AlrGst have indicated that a positive charge at this
position is essential for efﬁcient catalysis owing to an elec-
trostatic interaction with Tyr2650 via His168 which results in a
lowering of the pKa of this important catalytic residue (Sun &
Toney, 1999). In addition, Arg219 is also proposed to aid in
the relative destabilization of the carbanionic intermediate by
preventing protonation of the pyridine ring N1, thereby
favouring racemization over other PLP-catalysed reactions
(Spies & Toney, 2003).
Lys131 in AlrSas is frequently carbamylated in alanine
racemases and this was ﬁrst reported in AlrGst (Morollo et al.,
1999). It was proposed that a carbamylated lysine in this
position would be important for the correct positioning and
charge modulation of Arg138. In AlrSas the density for Lys131
is not consistent with carbamylation and in addition there is
poor density for the side chain of Arg138, implying that this
residue may be poorly ordered. Notably, in place of a carba-
mylated lysine the AlrSas structure contains a bound sulfate
molecule. This sulfate in AlrSas interacts with the side chain of
Lys131 and His200 and is within hydrogen-bonding distance of
Arg138. A sulfate at this location has not been observed in
the active sites of other alanine racemases, but reinforces the
notion that a negative charge at this position is important for
structural integrity in this region of the enzyme. Alanine
racemases such as AlrBax that lack a Lys129 equivalent have
been shown in at least one case to utilize a chloride ion which
may assume the same function as the carbamylated lysine
(Coun ˜ago et al., 2009). However, in the AlrSas structure, while
it looks as if this sulfate is substituting for a carbamate or
chloride ion at this position, it is likely to be too bulky and
highly charged to do so effectively, which may offer an
explanation as to why Arg138 is poorly ordered.
It is likely that the absence of carbamylation of Lys131
in AlrSas is a consequence of the low pH (5.0) at which the
enzyme was crystallized, an effect which has been reported
previously for the Class D OXA-10  -lactamase (Golemi et al.,
2001). AlrGst and DadXPao (Morollo et al., 1999; LeMagueres
et al., 2003), both of which demonstrate carbamylation of the
equivalent lysine residue, were crystallized at a much higher
pH than AlrSas (8.5 and 7.5, respectively). It could not be
established whether AlrMtb, which was crystallized at pH 9.2,
is carbamylated because of poor electron density for the side
chain of the lysine residue corresponding to this position
(LeMagueres et al., 2005).
In the structure of AlrSas there is one acetate, which is a
weak inhibitor of alanine racemase, per active site. The
carboxylate group of the AlrSas acetate forms a hydrogen bond
to Met3120 NH, analogous to the interactions made by the
carboxylate group of alanine (Watanabe et al., 2002). In
addition, the carboxylate bound at this location also interacts
with ordered water molecules in each active site (wat2091 and
wat2078). These acetates are both bound near to the estab-
lished substrate-binding site where other negatively charged
inhibitors such as 1-aminoethylphosphonic acid (l-Ala-P) and
propionate have also been observed (Stamper et al., 1998;
Morollo et al., 1999). Acetate is a feature of the active sites of
AlrGst and AlrBax, both of which require acetate for crystal-
lization (Shaw et al., 1997; Coun ˜ago et al., 2009). In these
structures acetate also hydrogen bonds to the guanidine group
of Arg138 and the phenolic O atom of Tyr2650, but these
interactions cannot be reported for AlrSas owing to the
absence of density for these two side chains. A consensus
acetate-binding site for alanine racemase can be constructed
by superposing the active sites from the four structures that
contain either bound acetate or propionate and then aver-
aging the locations of the acetate ligands. Analysis of this
consensus acetate site indicates that it is well conserved, with
r.m.s. deviations from this site of 0.43 A ˚ for AlrSas,0 . 6 6A ˚ for
AlrGst,0 . 7 4 A ˚ for AlrGst propionate and ﬁnally 0.9 A ˚ for
AlrBax.
3.4. Active-site entryway
In agreement with previous structural analyses, the active-
site entryway of AlrSas is comprised of residues from both
monomers and is roughly conical in shape, with the base of the
cone oriented towards the outside of the enzyme. The narrow
entryway consists of outer, middle and inner layers, which
become increasingly constricted leading towards the PLP
cofactor. As demonstrated in Fig. 2, the residues contributing
to the inner (Ala172, Tyr2650, Tyr2840 and Tyr354) and middle
(Asp173, Arg2900, Arg309 and Ile352) layers of the AlrSas
entryway are highly conserved between the compared alanine
racemases. The residues which form the outer layer of the
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enzymes (LeMagueres et al., 2005). While the active-site
binding pockets of alanine racemases are large enough to bind
inhibitors, the constricted nature of the entryway could make
it problematic for larger compounds to gain access to the
active site. Structural studies of DadXPao indicate that the
greatest restriction in the entryway is between two tyrosines
from the inner layer (Tyr2530 and Tyr341, DadXPao num-
bering), which are around 2.7 A ˚ apart (LeMagueres et al.,
2003). At such a narrow distance one or both of these residues
must move in order to permit even small substrates, namely
enantiomers of alanine, to enter and leave the active site.
Proteolytic digestion experiments in S. typhimurium (Gala-
katos & Walsh, 1987) suggest that the catalytic tyrosine
(Tyr2650 in AlrSas) is part of a conserved ﬂexible loop in the
entryway of the active site and mutational studies in G. stearo-
thermophilus (Patrick et al., 2002) suggest that the juxtaposed
tyrosine (Tyr354 in AlrSas) also plays a role in controlling
substrate speciﬁcity. It may be possible, however, to direct
drug-design efforts at residues that form the conserved
portion of the entryway but do not need to extend beyond
these two gating tyrosines (Im et al., 2011).
The conserved active-site entryway, dimer interface and
active-site binding pocket of alanine racemase are possible
targets for structure-aided drug design. In each of these areas,
the targeting of multiple residues as opposed to a single site
(such as the enzyme cofactor) could be advantageous for the
development of drugs with greater speciﬁcity for alanine
racemases. The structural determination and biochemical
characterization of AlrSas presented here will provide a
template for future structure-based drug-design studies of the
enzyme, with the ultimate goal of developing new treatments
for antibiotic-resistant strains of S. aureus.
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